-transparent.png){kind=logo}
A killed armadillo-derived Mycobacterium leprae vaccine was examined for its ability to induce a delayed-type hypersensitivity (DTH) response in purified protein derivative (PPD)-positive human volunteers living in a leprosy non-endemic country. Four groups of individuals aged between 23 and 28 years were given 1.5 x 10(7), 5 x 10(7), 1.5 x 10(8) and 5 x 10(8)M. leprae intradermally. A marked increase in reactivity to the M. leprae-derived skin test antigen (MLSA) was observed in the vaccinated groups receiving the three highest doses of vaccine while there was very little change observed in their PPD reactivity. No unacceptable side-effects attributable to the vaccine were observed. The killed armadillo-derived M. leprae vaccine thus appears to be able to induce a DTH response in man at doses which do not cause unacceptable side-effects.
H K Gill, and
A S Mustafa, and
T Godal
January 1986,
Bulletin of the Pan American Health Organization,
H K Gill, and
A S Mustafa, and
T Godal
June 1997,
Leprosy review,
H K Gill, and
A S Mustafa, and
T Godal
June 1981,
Clinical and experimental immunology,
H K Gill, and
A S Mustafa, and
T Godal
August 1998,
International journal of epidemiology,
H K Gill, and
A S Mustafa, and
T Godal
June 1981,
Clinical and experimental immunology,
H K Gill, and
A S Mustafa, and
T Godal
January 1990,
Nihon Rai Gakkai zasshi,
H K Gill, and
A S Mustafa, and
T Godal
January 1993,
Vaccine,
H K Gill, and
A S Mustafa, and
T Godal
March 2002,
Vaccine,
H K Gill, and
A S Mustafa, and
T Godal
March 1997,
International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association,
H K Gill, and
A S Mustafa, and
T Godal
January 1986,
Nihon Rai Gakkai zasshi,
